A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer

Clinical trial NCT03430063 · TERMINATED

Trial details

NCT number: NCT03430063
Sponsor: Regeneron Pharmaceuticals
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Advanced Non-Small Cell Lung Carcinoma

Start date: 2018-05-29
Primary completion: 2021-10-27
Enrollment: 28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.